|
1
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Miller K and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang ML, Huang ZZ and Zheng Y: Estimates
and prediction on indidence, mortality and prevalence of breast
cancer in China, 2008. Zhonghua Liu Xing Bing Xue Za Zhi.
33:1049–1051. 2012.(In Chinese). PubMed/NCBI
|
|
5
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumors. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Si W, Li Y, Han Y, Zhang F, Wang Y, Li Y,
Linghu RX, Zhang X and Yang J: Epidemiological and
clinicopathological trends of breast cancer in chinese patients
during 1993 to 2013: A retrospective study. Medicine (Baltimore).
94:e8202015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tran B and Bedard PL: Luminal-B breast
cancer and novel therapeutic targets. Breast Cancer Res.
13:2212011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grosso JF and Jure-Kunkel MN: CTLA-4
blockade in tumor models: An overview of preclinical and
translational research. Cancer Immun. 13:52013.PubMed/NCBI
|
|
9
|
Schwartz JC, Zhang X, Fedorov AA,
Nathenson SG and Almo SC: Structural basis for co-stimulation by
the human CTLA-4/B7-2 complex. Nature. 410:604–608. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu H, Yang J, Jiao S, Li Y, Zhang W and
Wang J: Cytotoxic T lymphocyte antigen 4 expression in human breast
cancer: Implications for prognosis. Cancer Immunol Immunother.
64:853–860. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao
W, Deng B, Sun J, Shao Q and Qu X: New Insights of CTLA-4 into its
biological function in breast cancer. Curr Cancer Drug Targets.
10:728–736. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Salvi S, Fontana V, Boccardo S, Merlo DF,
Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M,
et al: Evaluation of CTLA-4 expression and relevance as a novel
prognostic factor in patients with non-small cell lung cancer.
Cancer Immunol Immunother. 61:1463–1472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH,
Kim SH, Chang H, Lee JO, Kim YJ, Lee HS, et al: Prognostic
implications of immunosuppressive protein expression in tumors as
well as immune cell infiltration within the tumor microenvironment
in gastric cancer. Gastric Cancer. 19:42–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laurent S, Carrega P, Saverino D, Piccioli
P, Camoriano M, Morabito A, Dozin B, Fontana V, Simone R, Mortara
L, et al: CTLA-4 is expressed by human monocyte-derived dendritic
cells and regulates their functions. Hum Immunol. 71:934–941. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang XF, Pan K, Weng DS, Chen CL, Wang
QJ, Zhao JJ, Pan QZ, Liu Q, Jiang SS, Li YQ, et al: Cytotoxic T
lymphocyte antigen-4 expression in esophageal carcinoma:
Implications for prognosis. Oncotarget. 7:26670–26679.
2016.PubMed/NCBI
|
|
16
|
Ehinger A, Malmström P, Bendahl PO, Elston
CW, Falck AK, Forsare C, Grabau D, Rydén L, Stål O and Fernö M;
South and South-East Swedish Breast Cancer Groups, : Histological
grade provides significant prognostic information in addition to
breast cancer subtypes defined according to St Gallen 2013. Acta
Oncol. 56:68–74. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members, :
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen international expert consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Prihantono P, Hatta M, Binekada C,
Sampepajung D, Haryasena H, Nelwan B, Asadul Islam A and Nilawati
Usman A: Ki-67 expression by immunohistochemistry and quantitative
real-time polymerase chain reaction as predictor of clinical
response to neoadjuvant chemotherapy in locally advanced breast
cancer. J Oncol. 2017:62098492017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Emens LA: Breast cancer immunobiology
driving immunotherapy: Vaccines and immune checkpoint blockade.
Expert Rev Anticancer Ther. 12:1597–1611. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koch MA, Thomas KN, Perdue NR, Smigiel KS,
Srivastava S and Campbell DJ: T-bet(+) Treg cells undergo abortive
Th1 cell differentiation due to impaired expression of IL-12
receptor β2. Immunity. 37:501–510. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu HM, Yang JL, Jiao SC, Wang JD and Li Y:
TGF-β1 precursor and CD8 are potential prognostic and predictive
markers in operated breast cancer. J Huazhong Univ Sci Technolog
Med Sci. 34:51–58. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vonderheide RH, LoRusso PM, Khalil M,
Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J,
Mariani GL, et al: Tremelimumab in combination with exemestane in
patients with advanced breast cancer and treatment-associated
modulation of inducible costimulator expression on patient T cells.
Clin Cancer Res. 16:3485–3494. 2010. View Article : Google Scholar : PubMed/NCBI
|
